Unauthorized HIV trial leader fined

HIV News LogoA Spanish researcher faces a penalty after conducting a study for which he never obtained proper approvals or insurance.

Spanish HIV/AIDS researcher Vicente Soriano, of Hospital Carlos III in Madrid, is facing a steep fine after violating regulations by conducting a clinical trial involving a new HIV drug without getting the appropriate approvals from Spain’s Agency for Medicines and Health Products.

A court of appeals levied the €210,000 ($283,689) fine against Soriano last month (January 14), but overturned a €6,000 ($8,105) fine issued to the researcher for obstructing the initial 2010 investigation into his apparent misdeeds.

Soriano was also charged with failing to obtain proper insurance for the trial and for informing trial participants that he had secured the hospital’s ethical clearance when he had in fact not done so. Soriano is appealing the fines.

The Phase 4 clinical trial started in 2009, when Soriano registered it on http://www.clinicaltrials.gov. The researchers’ aim was to determine if HIV patients with undetectable levels of the virus in their blood could swap out protease inhibitors with a new integrase inhibitor called raltegravir to improve their outcomes and suffer fewer side effects. More than 300 subjects enrolled in the trial, and Soriano and several coauthors published a 2010 HIV Clinical Trials paper reporting that raltegravir sustained viral suppression in most of the subjects who were followed for 24 weeks.

Unauthorized HIV trial leader fined.


Share your thoughts

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s